目的：观察银杏叶片对土三七诱导的大鼠肝小静脉闭塞病（HVOD）的干预作用。方法雌性SD大鼠42只，采用土三七诱导建立大鼠HVOD模型，随机分为对照组10只，模型组12只，银杏叶片低、高剂量组10只。对照组大鼠给予蒸馏水7mL/（kg·d）灌胃；模型组给予土三七浓缩煎液7mL/（kg·d）灌胃；银杏叶片低、高剂量组分别给予土三七提取液[7mL/（kg·d）]+银杏叶片[50mg/（kg·d）]、土三七提取液[7mL/（kg·d）]+银杏叶片[100mg/（kg·d）]灌胃；4周后处死大鼠，采集血清、肝组织，检测血清学指标、观察肝组织病理学变化，评价肝脏胶原表达及纤维化程度。结果银杏叶片低、高剂量组大鼠总胆红素（TBILI）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、血清透明质酸（HA）、Ⅲ型前胶原（PCⅢ）等较模型组均有显著降低[TBILI：（2.43±1.00）μmol/L、（2.28±0.55）μmol/L比（6.02±1.26）μmol/L，P<0.05；ALT：（117.44±35.24）U/L、（98.13±13.50）U/L比（143.54±23.25）U/L，P<0.05，P<0.01；AST：（220.44±48.13）U/L、（198.20±41.64）U/L比（303.92±51.53）U/L，P<0.05，P<0.01；HA：（157.80±41.63）ng/mL、（162.63±13.48）ng/mL比（189.72±23.30）ng/mL，P<0.05，P<0.01；PCⅢ：（16.26±2.86）ng/mL、（14.40±1.73）ng/mL比（20.50±4.52）ng/mL，P<0.05，P<0.01]；银杏叶片低、高剂量组大鼠血白蛋白（ALB）较模型组显著增加[（31.95±1.64）、（32.48±1.33）g/L比（29.08±3.62）ng/L，P<0.05]，银杏叶片高剂量组Ⅳ型胶原（Ⅳ-C）较低剂量治疗组下降更明显[（2.58±0.36）ng/mL比（3.16±0.76）ng/mL，P<0.05]；病理学检查示，银杏叶片各剂量组较模型组肝纤维化程度轻，其中高剂量组改善更显著。结论银杏叶片对土三七诱导的大鼠HVOD有明显的防治作用。%Objective To investigate the effects of Ginkgo biloba tablets on Gynura segetum-induced hepatic veno-occlusive disease in rats. Methods Forty-two female SD rats were randomly divided into 4 groups: control group(n=10), model group(n=12), low-dose and high-dose Ginkgo prophylaxis groups(n=10). Control group was given distilled water. Model group was given Gynura segetum water decoction (7mL·kg-1·d-1). Ginkgo prophylaxis groups received a mixture of gynura segetum water decoction(7mL·kg-1·d-1) and ginkgo biloba(50 or 100mg·kg-1·d-1). All rats were sacrificed 4 weeks later to collect blood and liver samples. Serum biochemistry parameters were mea-sured, the liver collagen expression and fibrosis were evaluated by using eosin(HE) staining. Results Ginkgo pro-phylaxis groups showed decreased TBIL, ALT, AST, HA, and PCIII compared with model group (TBILI: 2.43 ± 1.00μmol/L, 2.28 ±0.55μmol/L vs 6.02 ±1.26μmol/L; ALT: 117.44 ±35.24U/L, 98.13 ±13.50U/L vs 143.54 ±23.25U/L;AST: 198.20 ±41.64U/L, 220.44 ±48.13U/L vs 303.92 ±51.53U/L; HA: 157.80 ±41.63ng/mL, 162.63 ±13.48ng/mL vs 189.72±23.30ng/mL; PCIII: 16.26±2.86ng/mL, 14.40±1.73ng/mL vs 20.50±4.52ng/mL; all P<0.05). The level of ALB was higher in Ginkgo biloba prophylaxis group than that in model group (31.95±1.64g/L, 32.48±1.33g/L vs 29.08± 3.62g/L, P<0.05). IV collagen in high-dose Ginkgo biloba prophylaxis group was lower than that in low-dose Ginkgo biloba prophylaxis group(2.58±0.36ng/mL vs 3.16±0.76ng/mL, P<0.05). The pathological examination showed liver fibrosis decreased in both Ginkgo biloba prophylaxis groups, especially in high-dose group. Conclusion Ginkgo biloba tablets have effect on prevention of HVOD-induced by Gynura segetum in rats.
展开▼
